Supercharging Immunotherapy

fancy black and blue t-cell 3d scientific images immune system

We work to reprogram the immune system to more effectively combat cancer and infectious diseases. We do this by using a technology that “supercharges” the natural ability of the immune system to combat disease.

3 Aug 2020

The United States Patent and Trademark Office (USPTO) and the European Patent…

22 Jun 2020

Interim data demonstrate that HB 101 is well tolerated and HB-101 elicits T…

19 Jun 2020

Sander van Deventer will continue to serve as a member of HOOKIPA’s Scientific…

16 Jun 2020

This IND allows HOOKIPA to initiate an additional arm in its Phase 1/2…

26 May 2020

Tune in to the webcast presentation on Wednesday, 3 June 2020 at 8:30 ET.

14 May 2020

The Company reports its financial results and corporate update for the first…

all news

The source of HOOKIPA’s strength lies in our people and the skills and experience that they bring. We want to continue to grow fast as a company and nurture a respectful and diverse culture that encourages teamwork. Attracting and retaining the best people is essential to achieve this. Please get in touch with us to find out more about our career opportunities.

Supercharging Immunotherapy

Our Mission

News

HOOKIPA Announces Issuance of US and European Patents

HOOKIPA Announces Positive Phase 2 Interim Safety and Immunogenicity Results…

HOOKIPA Announces Changes to its Board of Directors – Resignation of Sander…

HOOKIPA Announces FDA Clearance of its IND Application for HB-202/201 Clinical…

HOOKIPA Pharma to Present at Jefferies Virtual Healthcare Conference

HOOKIPA Pharma Reports First Quarter 2020 Financial Results and Provides a…

Our Pipeline

Careers